atovaquone has been researched along with Ocular Toxoplasmosis in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chorlton, SD | 1 |
| Fekrat, S; Proia, AD; Rao, V; Schneider, E | 1 |
| Crutchley, C; Dubey, JP | 1 |
| Androudi, S; Bhaila, I; Fiore, T; Iaccheri, B; Janjua, S; Papadaki, T; Stephen Foster, C | 1 |
| Godehardt, E; Joussen, AM; Maier, AK; Severing, K; Stammen, J; Winterhalter, S | 1 |
| Freund, KB; Holland, GN; Kreiger, AE; Nguyen, QD; Vance, SK; Wenick, AS | 1 |
| Baatz, H; Gümbel, H; Hattenbach, LO; Mirshahi, A; Puchta, J | 1 |
| Althaus, C; Armbrecht, C; Jablonowski, H; Schimkat, M; Sundmacher, R | 1 |
| Althaus, C; Hudde, T; Schimkat, M; Sundmacher, R | 1 |
| Gormley, PD; Lightman, S; Minnasian, D; Pavesio, CE | 1 |
| Jaffe, GJ; Pearson, PA; Piracha, AR; Sen, HA | 1 |
| de Smet, MD; Lopez, JS; Masur, H; Mueller, BU; Nussenblatt, RB; Pizzo, PA | 1 |
2 trial(s) available for atovaquone and Ocular Toxoplasmosis
| Article | Year |
|---|---|
Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Atovaquone; Chorioretinitis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Secondary Prevention; Toxoplasmosis, Ocular; Visual Acuity; Young Adult | 2010 |
Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Atovaquone; Chorioretinitis; Drug Evaluation; Female; Follow-Up Studies; Fundus Oculi; Humans; Immunocompetence; Middle Aged; Naphthoquinones; Prospective Studies; Safety; Toxoplasmosis, Ocular; Treatment Outcome; Visual Acuity | 1999 |
10 other study(ies) available for atovaquone and Ocular Toxoplasmosis
| Article | Year |
|---|---|
Adjunctive bradyzoite-directed therapy for reducing complications of congenital toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Atovaquone; Brain; Chorioretinitis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eye; Humans; Infant; Infant, Newborn; Mice; Models, Biological; Recurrence; Spiramycin; Toxoplasma; Toxoplasmosis, Animal; Toxoplasmosis, Cerebral; Toxoplasmosis, Congenital; Toxoplasmosis, Ocular | 2019 |
Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
Topics: Adenocarcinoma; Anti-Infective Agents; Atovaquone; Chorioretinitis; ErbB Receptors; Erlotinib Hydrochloride; Female; Food Parasitology; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Toxoplasma; Toxoplasmosis, Ocular | 2014 |
Toxoplasmosis in wallabies (Macropus rufogriseus and Macropus eugenii): blindness, treatment with atovaquone, and isolation of Toxoplasma gondii.
Topics: Animals; Anti-Infective Agents; Atovaquone; Biological Assay; Cats; Female; Macropodidae; Male; Mice; Toxoplasma; Toxoplasmosis, Animal; Toxoplasmosis, Ocular | 2008 |
Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review.
Topics: Adolescent; Adult; Atovaquone; Clindamycin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Gastrointestinal Diseases; Humans; Male; Medical Records; Middle Aged; Pyrimethamine; Retrospective Studies; Sulfadiazine; Sulfamethoxazole; Toxoplasmosis, Ocular; Trimethoprim; Vitreous Body; Young Adult | 2008 |
Diagnostic and therapeutic challenges.
Topics: Adult; Anti-Infective Agents; Atovaquone; Chorioretinitis; Diagnosis, Differential; Eye Diseases; Female; Fluorescein Angiography; Humans; Recurrence; Tomography, Optical Coherence; Toxoplasmosis, Ocular; Visual Acuity; Vitreous Body | 2011 |
Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient.
Topics: Adult; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Atovaquone; Chorioretinitis; Drug Resistance, Microbial; Female; Humans; Immunocompetence; Naphthoquinones; Oxidoreductases; Recurrence; Toxoplasma; Toxoplasmosis, Ocular; Visual Acuity | 2006 |
[Treatment of toxoplasmosis retinochoroiditis with atovaquone in an AIDS patient].
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Atovaquone; Chorioretinitis; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorescein Angiography; Follow-Up Studies; Humans; Male; Middle Aged; Naphthoquinones; Toxoplasmosis, Ocular | 1995 |
[Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient].
Topics: Adult; Animals; Antiprotozoal Agents; Atovaquone; Chorioretinitis; Female; Follow-Up Studies; Humans; Male; Naphthoquinones; Recurrence; Toxoplasma; Toxoplasmosis, Ocular | 1996 |
Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Atovaquone; Brain; Chorioretinitis; Chronic Disease; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Female; Mesocricetus; Naphthoquinones; Retina; Toxoplasma; Toxoplasmosis, Cerebral; Toxoplasmosis, Ocular | 1998 |
Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiprotozoal Agents; Atovaquone; Eye Infections, Parasitic; Follow-Up Studies; Fundus Oculi; Humans; Male; Naphthoquinones; Toxoplasmosis, Ocular | 1992 |